Altered immune phenotypes in subjects with Fabry disease and responses to switching from agalsidase alfa to agalsidase beta.

Fabry disease agalsidase alfa agalsidase beta enzyme replacement therapy immune alterations immune cells lyso-Gb3

Journal

American journal of translational research
ISSN: 1943-8141
Titre abrégé: Am J Transl Res
Pays: United States
ID NLM: 101493030

Informations de publication

Date de publication:
2019
Historique:
received: 06 06 2018
accepted: 02 01 2019
entrez: 12 4 2019
pubmed: 12 4 2019
medline: 12 4 2019
Statut: epublish

Résumé

Fabry disease (FD) is a rare X-linked genetic disorder caused by mutations in the

Identifiants

pubmed: 30972193
pmc: PMC6456521

Types de publication

Journal Article

Langues

eng

Pagination

1683-1696

Déclaration de conflit d'intérêts

None.

Références

Ann Neurol. 2000 Feb;47(2):229-33
pubmed: 10665494
Rapid Commun Mass Spectrom. 2002;16(16):1507-14
pubmed: 12203240
Glycobiology. 2003 Apr;13(4):305-13
pubmed: 12626384
J Inherit Metab Dis. 2005;28(1):21-33
pubmed: 15702403
J Hum Genet. 2006;51(3):180-8
pubmed: 16372133
Int J Clin Pract. 2007 Feb;61(2):293-302
pubmed: 17263716
Acta Neuropathol. 2008 Feb;115(2):159-74
pubmed: 17924126
Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):2812-7
pubmed: 18287059
J Inherit Metab Dis. 2009 Dec;32 Suppl 1:S67-77
pubmed: 19259782
Clin Chim Acta. 2009 May;403(1-2):194-7
pubmed: 19268437
Clin J Am Soc Nephrol. 2010 Feb;5(2):371-8
pubmed: 20007680
Orphanet J Rare Dis. 2010 Nov 22;5:30
pubmed: 21092187
Mol Genet Metab. 2011 Jan;102(1):99-102
pubmed: 21123099
Anal Chem. 2012 Mar 20;84(6):2745-53
pubmed: 22309310
Curr Med Chem. 2012;19(19):3241-52
pubmed: 22612706
Annu Rev Genomics Hum Genet. 2012;13:307-35
pubmed: 22970722
Curr Med Chem. 2013;20(2):280-8
pubmed: 23092136
Anal Chem. 2013 Feb 5;85(3):1743-52
pubmed: 23248976
Anal Chem. 2014 Apr 1;86(7):3476-83
pubmed: 24634980
Clin Chim Acta. 2015 Jan 1;438:195-204
pubmed: 25149322
JIMD Rep. 2015;22:1-10
pubmed: 25690728
JIMD Rep. 2016;25:95-106
pubmed: 26303609
Eur J Immunol. 2016 Jan;46(1):147-53
pubmed: 26426881
Blood Cells Mol Dis. 2016 Jul;59:8-15
pubmed: 27282561
Curr Protoc Hum Genet. 2016 Jul 01;90:17.22.1-17.22.12
pubmed: 27367162
Genet Med. 2017 Mar;19(3):275-282
pubmed: 27608175
Mol Genet Metab. 2017 Jan - Feb;120(1-2):57-61
pubmed: 27773586
PLoS One. 2016 Dec 12;11(12):e0168135
pubmed: 27942037
Immunol Lett. 2017 Aug;188:79-85
pubmed: 28687233
Mol Genet Metab. 2017 Nov;122(3):19-27
pubmed: 28947349
Clin Exp Nephrol. 2018 Aug;22(4):843-849
pubmed: 29288396
Mol Genet Metab. 2018 Apr;123(4):416-427
pubmed: 29530533

Auteurs

Renuka P Limgala (RP)

Lysosomal and Rare Disorders Research and Treatment Center (LDRTC) Fairfax, VA 22030, USA.

Tabitha Jennelle (T)

Lysosomal and Rare Disorders Research and Treatment Center (LDRTC) Fairfax, VA 22030, USA.

Matthew Plassmeyer (M)

Amerimmune, O & O Alpan, LLC Fairfax, VA 22030, USA.

Michel Boutin (M)

Division of Medical Genetics, Department of Pediatrics, Université de Sherbrooke Sherbrooke, Quebec, Canada.

Pamela Lavoie (P)

Division of Medical Genetics, Department of Pediatrics, Université de Sherbrooke Sherbrooke, Quebec, Canada.

Mona Abaoui (M)

Division of Medical Genetics, Department of Pediatrics, Université de Sherbrooke Sherbrooke, Quebec, Canada.

Christiane Auray-Blais (C)

Division of Medical Genetics, Department of Pediatrics, Université de Sherbrooke Sherbrooke, Quebec, Canada.

Khan Nedd (K)

Infusion Associates Grand Rapids, MI 49525, USA.

Oral Alpan (O)

Amerimmune, O & O Alpan, LLC Fairfax, VA 22030, USA.

Ozlem Goker-Alpan (O)

Lysosomal and Rare Disorders Research and Treatment Center (LDRTC) Fairfax, VA 22030, USA.

Classifications MeSH